{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=sacubitril%2Fvalsartan",
    "query": {
      "intervention": "sacubitril/valsartan"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 62,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=sacubitril%2Fvalsartan&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T02:25:44.785Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00549770",
      "title": "Efficacy and Safety of LCZ696A in Patients With Essential Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "LCZ696",
          "type": "DRUG"
        },
        {
          "name": "Valsartan",
          "type": "DRUG"
        },
        {
          "name": "AHU377",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1334,
      "start_date": "2007-09",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2015-08-25",
      "last_synced_at": "2026-09-02T02:25:44.785Z",
      "location_count": 38,
      "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Fair Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00549770"
    },
    {
      "nct_id": "NCT02788656",
      "title": "Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Congestive Heart Failure"
      ],
      "interventions": [
        {
          "name": "Implantable Hemodynamic Monitor",
          "type": "DEVICE"
        },
        {
          "name": "Angiotensin-Converting Enzyme Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Angiotensin II Type 1 Receptor Blocker",
          "type": "DRUG"
        },
        {
          "name": "sacubitril/valsartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2016-09",
      "completion_date": "2018-11-09",
      "has_results": true,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-09-02T02:25:44.785Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02788656"
    },
    {
      "nct_id": "NCT05096039",
      "title": "Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Sacubitril/valsartan",
          "type": "DRUG"
        },
        {
          "name": "ACEI or ARB and no sacubitril/valsartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 1614719,
      "start_date": "2020-04-10",
      "completion_date": "2020-09-30",
      "has_results": false,
      "last_update_posted_date": "2021-12-16",
      "last_synced_at": "2026-09-02T02:25:44.785Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05096039"
    },
    {
      "nct_id": "NCT02924727",
      "title": "Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Myocardial Infarction"
      ],
      "interventions": [
        {
          "name": "LCZ696 (sacubitril/valsartan)",
          "type": "DRUG"
        },
        {
          "name": "Ramipril",
          "type": "DRUG"
        },
        {
          "name": "Placebo of LCZ696",
          "type": "DRUG"
        },
        {
          "name": "Placebo of ramipril",
          "type": "DRUG"
        },
        {
          "name": "Valsartan",
          "type": "DRUG"
        },
        {
          "name": "Placebo of valsartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5669,
      "start_date": "2016-12-09",
      "completion_date": "2021-02-26",
      "has_results": true,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-09-02T02:25:44.785Z",
      "location_count": 81,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 74 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02924727"
    },
    {
      "nct_id": "NCT03785405",
      "title": "Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "sacubitril/valsartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": 216,
      "start_date": "2019-05-02",
      "completion_date": "2023-12-29",
      "has_results": true,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-09-02T02:25:44.785Z",
      "location_count": 15,
      "location_summary": "Loma Linda, California • Los Angeles, California • Palo Alto, California + 12 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03785405"
    },
    {
      "nct_id": "NCT04743063",
      "title": "Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Heart Failure, Systolic",
        "Frailty"
      ],
      "interventions": [
        {
          "name": "sacubitril/valsartan",
          "type": "DRUG"
        },
        {
          "name": "Angiotensin II Receptor Blockers",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 40000,
      "start_date": "2021-01-14",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-02-15",
      "last_synced_at": "2026-09-02T02:25:44.785Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04743063"
    },
    {
      "nct_id": "NCT05963282",
      "title": "Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "de Novo Heart Failure"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9870,
      "start_date": "2021-11-29",
      "completion_date": "2022-07-19",
      "has_results": false,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-09-02T02:25:44.785Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05963282"
    },
    {
      "nct_id": "NCT01922089",
      "title": "Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure With Reduced Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "LCZ696",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 498,
      "start_date": "2013-11",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2015-10-15",
      "last_synced_at": "2026-09-02T02:25:44.785Z",
      "location_count": 22,
      "location_summary": "Anchorage, Alaska • Gilbert, Arizona • Tucson, Arizona + 18 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01922089"
    },
    {
      "nct_id": "NCT05194111",
      "title": "Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure",
        "Heart Dysfunction"
      ],
      "interventions": [
        {
          "name": "Sacubitril-valsartan",
          "type": "DRUG"
        },
        {
          "name": "Valsartan",
          "type": "DRUG"
        },
        {
          "name": "Carvedilol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 70,
      "start_date": "2022-08-11",
      "completion_date": "2028-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-09-02T02:25:44.785Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05194111"
    },
    {
      "nct_id": "NCT04055428",
      "title": "NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus",
        "Cardiovascular Diseases",
        "Insulin Sensitivity/Resistance",
        "Metabolic Disease",
        "Natriuretic Peptides",
        "Metabolism",
        "Energy Expenditure"
      ],
      "interventions": [
        {
          "name": "Sacubitril, Valsartan 97-103 mg Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Valsartan 160 mg",
          "type": "DRUG"
        },
        {
          "name": "Intravenous Glucose Tolerance Test",
          "type": "OTHER"
        },
        {
          "name": "Standardized Meals",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Exercise capacity VO2 maximum determination",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2020-08-15",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-09-02T02:25:44.785Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04055428"
    }
  ]
}